A Free CME/CNE Dinner Meeting



Advances in Multiple Sclerosis Research and Treatment:

Highlights from the 2008 WORLD CONGRESS

You may register via fax, e-mail, or phone. When you register, it is **imperative** that you provide the following information: first name, last name, address, phone number, fax number or e-mail address, and the title **World Congress.**

3 Methods to Register

Confirmation of registration will be provided.

FAX THIS FORM TO:	PHONE:	E-MAIL:
866-302-4938	866-482-4263, ext. 126	neurology@chesteredgroup.com

NAME _____ TITLE _____

SPECIALTY _____ AFFILIATION OR PRACTICE NAME _____

ADDRESS _____

CITY _____ STATE _____ ZIP CODE _____

PHONE _____ EXT. _____ FAX _____

E-MAIL _____

I understand that by providing my fax number I consent to receive faxes sent by or on behalf of CMK (and its subsidiaries and affiliates). I understand that CMK will not share my fax number with other organizations.

Signature: _____ Date: _____

Date:
Place:

Please answer these brief preactivity questions by checking the appropriate box.

How would you rate your confidence in your ability to:

Discuss recent data on the immunopathology of MS and describe its clinical relevance?	❑ 1 Low	❑ 2	❑ 3	❑ 4	❑ 5 High
Identify emerging surrogate markers and new imaging techniques that may be useful in clinical practice?	❑ 1 Low	❑ 2	❑ 3	❑ 4	❑ 5 High
Summarize data regarding new MS therapies and new treatment trials?	❑ 1 Low	❑ 2	❑ 3	❑ 4	❑ 5 High

CME/CE INFORMATION

Needs Statement

Multiple sclerosis (MS) is a chronic, usually progressive central nervous system (CNS) disorder that typically requires long-term treatment.[1] As more is learned about the complex immune mechanisms and the pathology involved in the initial inflammatory and the chronic phases of MS, immune-based therapies continue to emerge, and best practices for their use are being established. Several disease-modifying therapies (DMTs) have been associated with reduced frequency of relapses and reduced brain lesion development.[2] The potential benefits of early initiation and consistent use of DMT are becoming evident, as more data from clinical trials become available.[3,4] Despite substantial advances, none of the currently available therapies is fully effective,[5] and managing suboptimal response remains a clinical challenge. While conventional MRI activity has been used as a marker of disease, mounting evidence suggests there may be a role for additional measures, such as brain atrophy, and for nonconventional imaging techniques such as magnetic resonance spectroscopy, magnetization transfer imaging, and functional MRI.[6] In light of rapid advances in the understanding of MS, the continual emergence of clinically relevant data, and evolving theories about best practices, it is critical that data and insights presented at major international congresses are disseminated promptly to neurologists and other clinicians involved in the care of patients with MS.

Educational Activity Objectives

Upon completion of this course, participants should be able to:

- Describe the emerging data on the immunopathology of MS and its clinical relevance
- Discuss emerging surrogate markers and new imaging techniques with clinical relevance
- Evaluate data regarding emerging MS therapies
- Evaluate data regarding new treatment trials

Target Audience

The target audience for this activity is neurologists, neuroscience nurses, and other healthcare providers who manage patients with MS.

Accreditation Statement

The Center for Medical Knowledge, LLC (CMK), is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Statements

CMK designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CHCE is approved as a provider of continuing nursing education by the North Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This activity is available for up to 1.5 Continuing Nursing Education (CNE) Contact Hours.

Faculty Disclosure

It is the policy of the sponsor to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. The speaker is expected to disclose to the participants any real or apparent conflict of interest related to the content of his/her presentation. CMK will identify and resolve all faculty conflicts of interest prior to the release of this activity. Faculty disclosure information will be provided in the course syllabus.

Commercial Support Acknowledgment

This activity is supported by an educational grant from Teva Neuroscience, Inc.

References

1. Pozzilli C, Prosperini L, Sbardella E, Paolillo A. Interferon after 10 years in patients with multiple sclerosis. *Neurol Sci.* 2006;27:S369-S372.
2. National Clinical Advisory Board of the National Multiple Sclerosis Society. Treatment recommendations for physicians: disease management consensus statement. 2007; http://www.nationalmssociety.org/forprofessionals/healthcare-professionals/publications/expert-opinion-papers/download.aspx?id=8. Accessed June 16, 2008.
3. Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinksy JS. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. *Mult Scler.* 2006;12:309-320.
4. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. *Neurology.* 2006;67:944-953.
5. Coyle PK. Switching algorithms: from one immunomodulatory agent to another. *J Neurol.* 2008;255(suppl 1):44-50.
6. Zivadinov R, Stosic M, Cox JL, Ramasamy DP, Dwyer MG. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. *J Neurol.* 2008;255(suppl 1):61-74.